179 related articles for article (PubMed ID: 24966922)
1. Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.
Hu GH; Liu H; Lai P; Guo ZF; Xu L; Yao XD; Zheng JH; Liu M; Xu YF
Int J Clin Exp Pathol; 2014; 7(5):2143-52. PubMed ID: 24966922
[TBL] [Abstract][Full Text] [Related]
2. Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4.
Huang QB; Ma X; Zhang X; Liu SW; Ai Q; Shi TP; Zhang Y; Gao Y; Fan Y; Ni D; Wang BJ; Li HZ; Zheng T
PLoS One; 2013; 8(6):e67294. PubMed ID: 23826258
[TBL] [Abstract][Full Text] [Related]
3. Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis.
Huang QB; Ma X; Li HZ; Ai Q; Liu SW; Zhang Y; Gao Y; Fan Y; Ni D; Wang BJ; Zhang X
Oncotarget; 2014 May; 5(10):3066-75. PubMed ID: 24931473
[TBL] [Abstract][Full Text] [Related]
4. Dicer suppresses MMP-2-mediated invasion and VEGFA-induced angiogenesis and serves as a promising prognostic biomarker in human clear cell renal cell carcinoma.
Chen YS; Meng F; Li HL; Liu QH; Hou PF; Bai J; Zheng JN
Oncotarget; 2016 Dec; 7(51):84299-84313. PubMed ID: 27732931
[TBL] [Abstract][Full Text] [Related]
5. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
6. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
7. Hsa_circ_0085576 promotes clear cell renal cell carcinoma tumorigenesis and metastasis through the miR-498/YAP1 axis.
Liu G; Zhou J; Piao Y; Zhao X; Zuo Y; Ji Z
Aging (Albany NY); 2020 Jun; 12(12):11530-11549. PubMed ID: 32541093
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
9. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
Sun HW; Wu C; Tan HY; Wang QS
Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
[TBL] [Abstract][Full Text] [Related]
10. The Vascular Notch Ligands Delta-Like Ligand 4 (DLL4) and Jagged1 (JAG1) Have Opposing Correlations with Microvascularization but a Uniform Prognostic Effect in Primary Glioblastoma: A Preliminary Study.
Qiu XX; Chen L; Wang CH; Lin ZX; Chen BJ; You N; Chen Y; Wang XF
World Neurosurg; 2016 Apr; 88():447-458. PubMed ID: 26546995
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Patel NS; Li JL; Generali D; Poulsom R; Cranston DW; Harris AL
Cancer Res; 2005 Oct; 65(19):8690-7. PubMed ID: 16204037
[TBL] [Abstract][Full Text] [Related]
12. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
13. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling.
Peng XS; Yang JP; Qiang YY; Sun R; Cao Y; Zheng LS; Peng LX; Lang YH; Mei Y; Li CZ; Meng DF; Liu ZJ; Wang MD; Zhou FJ; Huang BJ; Qian CN
Mol Cancer Res; 2020 Jun; 18(6):903-912. PubMed ID: 32169891
[TBL] [Abstract][Full Text] [Related]
14. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
[TBL] [Abstract][Full Text] [Related]
15. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
16. Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer.
Yang MH; Chang KJ; Li B; Chen WS
Biomed Res Int; 2019; 2019():4647252. PubMed ID: 31093499
[TBL] [Abstract][Full Text] [Related]
17. Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells.
Li GG; Li L; Li C; Ye LY; Li XW; Liu DR; Bao Q; Zheng YX; Xiang DP; Chen L; Chen J
World J Gastroenterol; 2013 Jul; 19(28):4486-94. PubMed ID: 23901223
[TBL] [Abstract][Full Text] [Related]
18. Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation.
Guo X; Duan Y; Ye X; Hu L; Xu T; Tong L; Yu M
Oncol Rep; 2018 Jul; 40(1):495-503. PubMed ID: 29749499
[TBL] [Abstract][Full Text] [Related]
19. Delta-like ligand 4 in hepatocellular carcinoma intrinsically promotes tumour growth and suppresses hepatitis B virus replication.
Kunanopparat A; Issara-Amphorn J; Leelahavanichkul A; Sanpavat A; Patumraj S; Tangkijvanich P; Palaga T; Hirankarn N
World J Gastroenterol; 2018 Sep; 24(34):3861-3870. PubMed ID: 30228780
[TBL] [Abstract][Full Text] [Related]
20. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
